Oncology – Gynecologic
Female erectile tissues and sexual dysfunction after pelvic radiotherapy: a scoping review.
13 Jul, 2022 | 11:23h | UTC
RCT | Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment.
12 Jul, 2022 | 11:51h | UTC
Commentary on Twitter
Updated results from the phase III ICON8 trial in 1,566 pts with newly diagnosed stage IC–IV epithelial ovarian, peritoneal or fallopian tube carcinoma reveal no statistically significant difference in OS with 3-weekly vs weekly carboplatin & paclitaxel: https://t.co/czgH7uGxjt
— NatureRevClinOncol (@NatRevClinOncol) June 15, 2022
RCT: Effect of Apatinib plus Pegylated Liposomal Doxorubicin vs. Pegylated Liposomal Doxorubicin alone on platinum-resistant recurrent ovarian cancer.
1 Jul, 2022 | 10:37h | UTCSee also: Visual Abstract
RCT: Maintenance Taxanes vs. surveillance in women with advanced ovarian/tubal/peritoneal cancer.
29 Jun, 2022 | 10:57h | UTCPhase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Consensus Statement: First-line PARP inhibitor maintenance for advanced, high-grade serous and endometrioid tubal, ovarian, and primary peritoneal cancers.
27 Jun, 2022 | 11:34h | UTC
International consensus statements on pre-invasive vulvar lesions.
23 Jun, 2022 | 10:21h | UTCNews Release: New Guidelines Address Treatment of Pre-Invasive Lesions of the Vulva – Wolters Kluwer Health: Lippincott
ESMO Guideline: Diagnosis, treatment, and follow-up of endometrial cancer.
13 Jun, 2022 | 08:08h | UTC
Screening every five years safe for women who test negative for HPV, study confirms.
9 Jun, 2022 | 11:26h | UTCNews Release: Screening every five years safe for women who test negative for HPV, study confirms – King’s College London
Editorial: HPV screening for cervical cancer is reaching maturity – The BMJ
Related WHO Guidance:
News release: New recommendations for screening and treatment to prevent cervical cancer – World Health Organization
Related USPSTF Guidance: Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement – JAMA
#ASCO22 – RCT: Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.
7 Jun, 2022 | 10:48h | UTC
A systematic review of the guidelines on venous thromboembolism prophylaxis in gynecologic oncology.
3 Jun, 2022 | 10:48h | UTC
M-A: Association between benign ovarian tumors and ovarian cancer risk.
2 Jun, 2022 | 10:18h | UTC
Retrospective Cohort Study | Ovarian cancer detection in average-risk women: classic- versus nonclassic-appearing adnexal lesions.
30 May, 2022 | 10:58h | UTCNews Release: Researchers use ultrasound to predict ovarian cancer – Radiological Society of North America
Commentary: Appearance of Ovarian Lesions on Ultrasound May Predict Malignancy – HealthDay
Commentary on Twitter
Classifying adnexal lesion appearance as classic or nonclassic has high sensitivity and specificity for diagnosing malignancy in women at average risk for ovarian cancer. @BaranLab @drantil7 @kpatellippmann @katematuren @ayakamaya @hanna_zrad @LizSadowski https://t.co/6NphOIycMe pic.twitter.com/99DyWIHXwU
— Radiology (@radiology_rsna) March 28, 2022
Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.
26 May, 2022 | 10:42h | UTC
Phase 1/2 RCT: Safety and efficacy of the mTOR inhibitor, Vistusertib, combined With Anastrozole in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.
26 May, 2022 | 10:30h | UTCSafety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Endocrine therapy is used in clinical practice in the management of relapsed or advanced HR + endometrial cancer. Anastrozole + vistusertib demonstrated clinically significant improvement with manageable adverse events, encouraging further research https://t.co/hHDtloSdNs #GynCSM
— JAMA Oncology (@JAMAOnc) May 12, 2022
Review: Outcomes of Enhanced Recovery after Surgery (ERAS) in gynecologic oncology.
6 May, 2022 | 10:22h | UTC
Review: Advances in radiation oncology for the treatment of cervical cancer.
6 May, 2022 | 10:20h | UTCAdvances in Radiation Oncology for the Treatment of Cervical Cancer – Current Oncology
RCT: Topical imiquimod versus surgery for vulvar intraepithelial neoplasia.
3 May, 2022 | 10:30h | UTCTopical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
RCT: Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma.
20 Apr, 2022 | 09:09h | UTCFuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Advanced testing for human papillomavirus infection improves prognostic evaluation in cervical cancer.
18 Apr, 2022 | 09:33h | UTCHuman Papillomavirus Infection Determines Prognosis in Cervical Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Study Confirms Favorable Prognosis for HPV-Positive Cervical Cancer— RNA sequencing identified more HPV+ tumors, showed 43% mortality disparity for HPV- tumors – MedPage Today (free registration required)
RCT: Rucaparib vs. standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation.
6 Apr, 2022 | 09:45h | UTCRucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In ARIEL4 phase III trial, pts with BRCA1/2-mut ovarian cancer who received ≥2 chemo regimens received rucaparib or chemo. In the ITT, mPFS was 7.4 mo vs 5.7 mo (HR 0.67, 95% CI 0.52–0.86; P = 0.0017). Three treatment-related deaths occurred w rucaparib https://t.co/G7j7djp6kV
— NatureRevClinOncol (@NatRevClinOncol) March 22, 2022
Cohort Study: Association of lower extremity lymphedema with physical functioning and activities of daily living among older survivors of colorectal, endometrial, and ovarian cancer.
28 Mar, 2022 | 08:39h | UTCCommentaries:
Lower-Extremity Lymphedema Common in Older, Female Cancer Survivors – HealthDay
Commentary on Twitter
Cohort study found nearly 1/3 of older female survivors of #ColorectalCancer, #EndometrialCancer, or #OvarianCancer have lower-extremity lymphedema (LEL), which is associated with worse physical function and needing assistance with ADLs. https://t.co/806Tt88TuV
— JAMA Network Open (@JAMANetworkOpen) March 9, 2022
SEOM-GEICO clinical guidelines on endometrial cancer.
25 Mar, 2022 | 08:24h | UTCSEOM-GEICO clinical guidelines on endometrial cancer (2021) – Clinical and Translational Oncology
[News release – not published yet] RCT: Minimally invasive approach to hysterectomy in cervical cancer is associated with poorer disease-free survival than open surgery.
24 Mar, 2022 | 08:47h | UTC
M-A: Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy in BRCA1/2 pathogenic variant (PV) carriers.
22 Mar, 2022 | 07:58h | UTC
Multi-disciplinary care planning of ovarian cancer in older patients.
18 Mar, 2022 | 07:55h | UTC